This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Prokarium Limited. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Michael Joseph Lacy: Innovator in Vaccine Development
Introduction
Michael Joseph Lacy is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of vaccine development, particularly through his innovative approaches to immunogenic Chlamydial peptides.
Latest Patents
Lacy holds a patent for an invention that provides an attenuated vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. This invention includes an attenuated vaccine vector with aroC and ssaV attenuating mutations. The heterologous polynucleotides are controlled by an inducible promoter, such as the assaG promoter. Notably, the immunogenic Chlamydial peptide can be a PmpG peptide, including variants like CT110, CT84, or CT40.
Career Highlights
Lacy's career is marked by his dedication to advancing vaccine technology. His work has the potential to impact public health positively by providing new avenues for combating Chlamydial infections.
Collaborations
Lacy has collaborated with esteemed colleagues, including Jonathan Lewis Telfer and Mark Richard Redfern, to further his research and development efforts.
Conclusion
Michael Joseph Lacy's innovative work in vaccine development showcases his commitment to improving health outcomes through scientific advancements. His contributions are vital in the ongoing fight against infectious diseases.